Key clinical trials at ADA 2019

The D2d study results will reveal whether daily vitamin D supplementation can slow the risk for progression to type 2 diabetes among people with impaired glucose regulation.

Friday 7 June: 11:30–12:30

The TODAY2 investigators will present their findings from the long-term monitoring of the children with type 2 diabetes who participated in the TODAY study.

Saturday 8 June: 13:45–15:45

Investigators for the PREVIEW diabetes prevention project will present their previously published findings for ADA attendees.

Saturday 8 June: 16:00–18:00

Investigators for the DECLARE-TIMI 58 trial of dapagliflozin cardiovascular safety will present their previously published findings for ADA attendees, as well as their latest analyses, including renal outcomes.

Sunday 9 June: 14:15–16:15

Following the publication of the pediatric medication and adult gastric banding studies, the RISE investigators will now present results showing whether early, intensive medication can preserve beta-cell function in adults with type 2 diabetes.

Sunday 9 June: 12:00–13:30

The REWIND investigators will report the cardiovascular safety of the weekly injectable glugacon-like peptide-1 receptor agonist dulaglutide in a lower-risk population than recruited to previous trials.

Sunday 9 June: 16:30–18:30

The much-anticipated CAROLINA trial pits a dipeptidyl peptidase-4 inhibitor against the active comparator of a sulfonylurea in patients with type 2 diabetes.

Monday 10 June: 16:30–18:30

Investigators for the previously published CREDENCE and CARMELINA trials will review the primary findings and present new analyses.

Tuesday 11 June: 7:30–9:30

The cardiovascular safety results for oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, will be revealed by the PIONEER 6 investigators in the last session of the ADA programme.

Tuesday 11 June: 9:45–11:45